SCHEMBL797886

SCHEMBL797886

COc1cc2nccc(Oc3ccc(NC(=O)c4c(I)ccn(-c5ccccc5)c4=O)cn3)c2cc1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 11/20 0.70
IGF1R P08069 5/20 0.69
KDR P35968 5/20 0.69
PTK2B Q14289 6/20 0.60
PTK2 Q05397 4/20 0.60
AURKA O14965 1/20 0.52
JAK2 O60674 1/20 0.52
RPS6KA5 O75582 1/20 0.52
ABL1 P00519 1/20 0.52
INSR P06213 1/20 0.52
LCK P06239 1/20 0.52
RET P07949 1/20 0.52
KIT P10721 1/20 0.52
PIM1 P11309 1/20 0.52
FGFR1 P11362 1/20 0.52
SRC P12931 1/20 0.52
PRKACA P17612 1/20 0.52
RPS6KB1 P23443 1/20 0.52
JAK1 P23458 1/20 0.52
MAPK3 P27361 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL797310 0.87 PTK2B (0.75) METIGF1RKDRPTK2BPTK2
SCHEMBL199503 0.84 PTK2B (0.82) METIGF1RKDRPTK2BPTK2
SCHEMBL201101 0.82 MET (1.00) METIGF1RKDRAURKAJAK2
SCHEMBL23142545 0.78 AXL (0.72) METIGF1RKDRAURKAJAK2
SCHEMBL31743141 0.78 AXL (0.72) METIGF1RKDRAURKAJAK2
SCHEMBL22923900 0.78 MET (0.61) METIGF1RKDRAXLPDGFRA
SCHEMBL1893668 0.78 PDGFRA (0.77) METIGF1RKDRKITPDGFRA
SCHEMBL30716545 0.76 PDGFRA (0.65) METKDRPTK2BPTK2KIT
SCHEMBL5049531 0.75 MET (1.00) METIGF1RKDR
SCHEMBL199176 0.75 PTK2B (1.00) METIGF1RKDRPTK2BPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET MET 3/4885IGF1R 57/4885KDR 200/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET MET 3/4885IGF1R 96/4885KDR 304/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET MET 3/4885IGF1R 57/4885KDR 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.